Professor | Tianfeng Xu | Asia Growth Partners

Name	Tianfeng Xu
Contact Information	tfxu@simm.ac.cn
Language ability	Chinese, English
Province	Shanghai

Name

Tianfeng Xu

Contact Information

tfxu@simm.ac.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2009-09--2014-07 PhD: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences 2005-09--2009-06 Bachelor's: Shandong Normal University
Work Experience	2014-11~2019-02 - University of Michigan-Ann Arbor - Postdoctoral Researcher 2009-09~2014-07 - Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences - PhD Student 2005-09~2009-06 - Shandong Normal University - Bachelor's Student
Awards	Guangdong Provincial Science and Technology Award (2016): Second Prize Guangzhou Science and Technology Award (2015): First Prize

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2009-09--2014-07 PhD: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
2005-09--2009-06 Bachelor's: Shandong Normal University

Work Experience

2014-11~2019-02 - University of Michigan-Ann Arbor - Postdoctoral Researcher
2009-09~2014-07 - Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences - PhD Student
2005-09~2009-06 - Shandong Normal University - Bachelor's Student

Awards

Guangdong Provincial Science and Technology Award (2016): Second Prize
Guangzhou Science and Technology Award (2015): First Prize

Areas of Focus	Small Molecule Drug Design and Synthesis
Publications	Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC degraders of Oncogenic KRASG12D, Tianfeng Xu, 2024 Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Associate Domain (TEAD) PROTAC Degraders, Tianfeng Xu, 2024 Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers, Tianfeng Xu, 2023 Design, Synthesis, and Bioevaluation of Pyrido2,3-dpyrimidin-7-ones as Potent SOS1 Inhibitors, Tianfeng Xu, 2023 Design, synthesis and structure-activity relationship studies of pyrido2,3-dpyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors, Tianfeng Xu, 2022 Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations, Tianfeng Xu, 2022 Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation, Tianfeng Xu, 2022 Structure-based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction, Tianfeng Xu, 2019 Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction, Tianfeng Xu, 2018 A structure-guided optimization of pyrido2,3-dpyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties, Tianfeng Xu, 2017 C5-substituted pyrido2,3-dpyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR(T790M) mutant, Tianfeng Xu, 2015 Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as Selective Inhibitors of EGFR Threonine790—Methionine790 (T790M) Mutants., Tianfeng Xu, 2013 Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido4,5-dpyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, Tianfeng Xu, 2013 Pyrimido4,5-dpyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine(790) to Methionine(790) (T790M) Mutants, Tianfeng Xu, 2013 Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine(790) -> Methionine(790) Mutant, Tianfeng Xu, 2012

Areas of Focus

Small Molecule Drug Design and Synthesis

Publications

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC degraders of Oncogenic KRASG12D, Tianfeng Xu, 2024
Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Associate Domain (TEAD) PROTAC Degraders, Tianfeng Xu, 2024
Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers, Tianfeng Xu, 2023
Design, Synthesis, and Bioevaluation of Pyrido2,3-dpyrimidin-7-ones as Potent SOS1 Inhibitors, Tianfeng Xu, 2023
Design, synthesis and structure-activity relationship studies of pyrido2,3-dpyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors, Tianfeng Xu, 2022
Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations, Tianfeng Xu, 2022
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation, Tianfeng Xu, 2022
Structure-based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction, Tianfeng Xu, 2019
Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction, Tianfeng Xu, 2018
A structure-guided optimization of pyrido2,3-dpyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties, Tianfeng Xu, 2017
C5-substituted pyrido2,3-dpyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR(T790M) mutant, Tianfeng Xu, 2015
Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as Selective Inhibitors of EGFR Threonine790—Methionine790 (T790M) Mutants., Tianfeng Xu, 2013
Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido4,5-dpyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, Tianfeng Xu, 2013
Pyrimido4,5-dpyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine(790) to Methionine(790) (T790M) Mutants, Tianfeng Xu, 2013
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine(790) -> Methionine(790) Mutant, Tianfeng Xu, 2012

Drug Design Synthesis Small Molecules Medicinal Chemistry Pharmacology Cancer Research Inhibitors Protac Tead Sos1

Xuechuan Hong - Wuhan University

Xianghai Cai - University of Chinese Academy of Sciences

Hu Na - University of Chinese Academy of Sciences

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us